Los Angeles Capital Management LLC lowered its stake in shares of Encompass Health Co. (NYSE:EHC – Get Rating) by 11.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 138,133 shares of the company’s stock after selling 17,909 shares during the quarter. Los Angeles Capital Management LLC owned about 0.14% of Encompass Health worth $8,262,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Bank of Montreal Can grew its holdings in shares of Encompass Health by 1.5% during the first quarter. Bank of Montreal Can now owns 11,340 shares of the company’s stock worth $806,000 after buying an additional 173 shares during the last quarter. Horrell Capital Management Inc. grew its holdings in shares of Encompass Health by 0.6% during the fourth quarter. Horrell Capital Management Inc. now owns 29,330 shares of the company’s stock worth $1,754,000 after buying an additional 185 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Encompass Health by 0.8% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the company’s stock worth $1,597,000 after buying an additional 200 shares during the last quarter. Creative Planning boosted its holdings in Encompass Health by 3.5% in the 2nd quarter. Creative Planning now owns 6,074 shares of the company’s stock valued at $340,000 after purchasing an additional 204 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC boosted its holdings in Encompass Health by 2.7% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 8,009 shares of the company’s stock valued at $479,000 after purchasing an additional 214 shares in the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on EHC. Truist Financial lifted their price objective on Encompass Health from $70.00 to $75.00 and gave the company a “buy” rating in a report on Thursday, February 9th. Barclays lifted their price objective on Encompass Health from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Tuesday, April 4th. Credit Suisse Group lifted their price objective on Encompass Health from $62.00 to $73.00 and gave the company an “outperform” rating in a report on Thursday, February 9th. Deutsche Bank Aktiengesellschaft lifted their price objective on Encompass Health from $62.00 to $70.00 in a report on Thursday, February 9th. Finally, Stephens reaffirmed an “overweight” rating and issued a $70.00 price objective on shares of Encompass Health in a report on Wednesday, February 8th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Encompass Health has an average rating of “Moderate Buy” and a consensus price target of $69.40.
Encompass Health Trading Down 0.4 %
Shares of Encompass Health stock opened at $63.44 on Friday. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.25 and a quick ratio of 1.25. Encompass Health Co. has a 1 year low of $44.33 and a 1 year high of $69.77. The company has a market capitalization of $6.33 billion, a P/E ratio of 23.50, a P/E/G ratio of 1.49 and a beta of 1.05. The business has a 50 day moving average price of $57.70 and a 200 day moving average price of $57.37.
Encompass Health (NYSE:EHC – Get Rating) last issued its quarterly earnings data on Tuesday, February 7th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.03. Encompass Health had a return on equity of 16.15% and a net margin of 5.54%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. Sell-side analysts anticipate that Encompass Health Co. will post 3.07 EPS for the current fiscal year.
Encompass Health Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, April 17th. Shareholders of record on Monday, April 3rd were issued a $0.15 dividend. The ex-dividend date was Friday, March 31st. This represents a $0.60 annualized dividend and a yield of 0.95%. Encompass Health’s dividend payout ratio (DPR) is presently 22.22%.
Insider Buying and Selling at Encompass Health
In other Encompass Health news, CFO Douglas E. Coltharp sold 17,895 shares of the business’s stock in a transaction on Friday, February 10th. The stock was sold at an average price of $60.78, for a total value of $1,087,658.10. Following the completion of the transaction, the chief financial officer now directly owns 53,097 shares in the company, valued at approximately $3,227,235.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.70% of the stock is currently owned by insiders.
Encompass Health Profile
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations.
Featured Stories
Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHC – Get Rating).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn’t on the list.
While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
